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Abstract: Lipoprotein subclass concentrations are modifiable markers of cardiovascular 
disease risk. Fenofibrate is known to show beneficial effects on lipoprotein subclasses, but 
little is known about the role of genetics in mediating the responses of lipoprotein 
subclasses to fenofibrate. A recent genomewide association study (GWAS) associated 
several single nucleotide polymorphisms (SNPs) with lipoprotein measures, and validated 
these associations in two independent populations. We used this information to construct 
genetic risk scores (GRSs) for fasting lipoprotein measures at baseline (pre-fenofibrate), and 
aimed to examine whether these GRSs also associated with the responses of lipoproteins to 
fenofibrate. Fourteen lipoprotein subclass measures were assayed in 817 men and women 
before and after a three week fenofibrate trial. We set significance at a Bonferroni 
corrected alpha <0.05 (p < 0.004). Twelve subclass measures changed with fenofibrate 
administration (each p = 0.003 to <0.0001). Mixed linear models which controlled for age, 
sex, body mass index (BMI), smoking status, pedigree and study-center, revealed that 
GRSs were associated with eight baseline lipoprotein measures (p < 0.004), however no 
GRS was associated with fenofibrate response. These results suggest that the mechanisms 
for changes in lipoprotein subclass concentrations with fenofibrate treatment are not 
mediated by the genetic risk for fasting levels. 
Keywords: pharmacogenetics; candidate gene study; lipoprotein; fenofibrate; NMR; 
GOLDN; genetic risk score; particle size; LDL size; HDL size 
 
1. Introduction 
Lipoproteins within the given fractions of very low-density, low-density, intermediate-density and 
high-density lipoproteins (VLDL, LDL, IDL and HDL respectively) can be further subdivided into 
small, medium and large subfractions based on size, which partially reflects the lipid and 
apolipoprotein content of the particle. Nuclear Magnetic Resonance Spectroscopy (NMR) is a method 
of characterizing lipoproteins in this manner, and can give information on the concentration of 
lipoproteins within a subfraction, as well as the average particle diameter within a fraction which 
reflects the constituent distribution of subfractions [1]. 
Specific distributions of lipoprotein subfractions, characterized by small LDL and large VLDL and 
HDL particles, demonstrate associations with disease states such as insulin resistance and 
atherosclerosis [2–7]. While the clinical utility of subfraction determination is still debated [8], the 
genetic association studies of the various NMR measures have shown promise as a method for helping 
to characterize the genetic underpinnings of lipoproteins. Several validated genetic markers have been 
associated with lipoprotein subclass concentrations and diameter measures in the fasting or 
postprandial states [9–11]. Although NMR measures are currently more expensive to collect than 
traditional enzymatic lipid measures, future clinical interest in lipoprotein subfractions may lie in the 
observation that subclass concentrations and distributions are modifiable, changing in response to 
exercise, diet and pharmacological interventions aimed at reducing atherosclerosis risk [12–16]. 
Fenofibrate is one such therapeutic agent. Indicated in hypertryglceridemia, fenofibrate reduces plasma 
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triglyceride (TG) levels by 35%–50%, while having simultaneous effects on other parameters such as 
markers of inflammation, cholesterol, and lipoprotein subclasses [17–22]. In particular, fenofibrate 
treatment is known to shift the LDL subclass towards larger LDL particles [14,18,23]. The effects on 
other lipoprotein subclasses are less well established, although a few human and mice studies suggest 
that overall VLDL size may decrease while HDL size and number may increase [24–26]. Responses to 
fenofibrate of traditional lipid phenotypes vary, some of which can be attributed to genetic effects [27–29]. 
As yet, we are aware of only two investigations into which genetic variants may associate with 
differences in lipoprotein subclass changes: a recent genome-wide association study (GWAS) reported 
that variants in the AHCYL2 reached and in the CD36 genes closely approached genome-wide levels of 
significance with VLDL and HDL diameter responses to fenofibrate, but was limited in its ability to 
only detect associations of relatively large effect [30]. A further study reported that the effect of 
fenofibrate on HDL subclasses may be dependent on ABCA1 polymorphisms, although these remain 
unreplicated [26]. This study further aimed to reveal associations between genetic variants with 
changes in lipoprotein subfraction concentrations and distributions. 
Using recently reported results from a large genome-wide association study meta-analysis for 
fasting NMR measures, we sought to examine whether these previously validated SNP-phenotype 
associations with fasting NMR measures also associate with the response of NMR measures to 
fenofibrate. First, we combined the SNPs into a GRSs relevant to each lipoprotein measures as there 
are differences in the SNP-phenotype associated with each phenotype. Next we sought to confirm that 
such GRSs replicated with fasting measures and subsequently, determine whether the GRSs predicted 
the response of these phenotypes to a three-week fenofibrate trial. 
2. Experimental Section 
2.1. Study Population 
The details of the GOLDN visits are published elsewhere [29] and depicted in Figure 1. GOLDN is 
part of the PROGENI (PROgram for GENetic Interaction) Network, a group of family intervention 
studies focusing on gene-environment interactions. The participants in the GOLDN study were mainly 
re-recruited from two NHLBI Family Heart Study (FHS) field centers: Minneapolis, MN, and Salt 
Lake City, UT. All subjects were of European ancestry. Eligibility criteria were: (1) ≥18 years of age; 
(2) fasting TGs <1500 mg/dL; (3) willing to participate in the study and attend the scheduled clinic 
exams; (4) member of a family with at least two members in a sibship; (5) AST and ALT results 
within normal range; and (6) creatinine ≤2.0 mg/dL. Exclusion criteria were: (1) history of liver, 
kidney, pancreas, gall bladder disease, or malabsorption; (2) current pregnancy; (3) insulin use; (4) use 
of lipid lowering drugs (including prescription, OTC and nutraceuticals; volunteers taking these agents 
were withdrawn from them at least three weeks prior to the study with physician’s approval); (5) use 
of warfarin; (6) women of childbearing potential not using an acceptable form of contraception;  
(7) known hypersensitivity to fenofibrate; and (8) history of pancreatitis within 12 months prior to 
enrollment. Previous data on these conditions were available from the parent study, and individuals not 
fulfilling inclusion criteria were not invited to participate. A medication questionnaire was 
administered on the first visit, which confirmed eligibility for inclusion. A previous study 
demonstrated that Caucasians in UT and MN were homogeneous and pooling data across centers 
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would not threaten the validity of this study [31]. From an initial sample size of 1238, we evaluated 
817 participants whom agreed to undergo the fenofibrate trial and are included in the analysis. 
Figure 1. Details of the GOLDN study. 
 
Adapted with permission from Frazier-Wood et al. 2012 [29]. 
After granting informed consent, participants underwent a baseline screening visit. This visit included 
the collection of demographic data and smoking status (current/non). The following day, participants came 
to the clinic for a fasting (8-h minimum) blood draw. The fenofibrate intervention followed, and consisted 
of a three-week treatment period, in which participants took fenofibrate (160 mg) daily. Lipoproteins were 
measured again, on the last day of the treatment period after another minimum 8-h fast. The GOLDN trial 
also included a high-fat meal challenge, with post-prandial blood measurements taken. As these data are 
not included in the present analyses, this part of the GOLDN protocol is not described. 
2.2. Biochemical Measurements 
All plasma samples used for this analysis were collected after an 8-h fast. All samples were 
analyzed for lipoprotein and lipid profiles once all collections were made in each study. 
NMR measures Measurements of VLDL, LDL and HDL diameter were determined by NMR 
spectroscopy. NMR detects the signal emitted by lipoprotein methyl-group protons when in the field of 
a magnet charged at 400 MHz. The NMR signal is decoded to obtain estimates of particle numbers for 
each of several lipoprotein fractions. The weighted average particle diameter for each lipoprotein fraction 
(VLDL, LDL and HDL) is calculated as the sum of the average lipoprotein particle diameters multiplied by 
the relative mass percentage, based on the amplitude of the methyl NMR signal and given in nanometers 
(nm). NMR groups intermediate-density lipoproteins (IDL) as a subclass of LDL [1,32]. The phenotypes 
available in GOLDN, and used in the current analyses are given in Table 1, alongside the range of 
diameters within each subfraction. In addition, mean diameter was available. 
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Traditional lipid measures Protocols for measuring TGs have been previously described [33,34]. 
Briefly, TGs were measured using the Roche/Hitachi 911 Automatic Analyzer (Roche Diagnostics 
Corporation, Indianapolis, IN, USA), using a glycerol blanked enzymatic method. The interlaboratory 
coefficients of variation in a pooled plasma control were 2.6%. Fasted TGs were available at two time 
points for a subsample of the current population (N = 748). The pairwise Pearson correlation between 
the two measures was high at r = 0.90 (p < 0.001). 
Table 1. Diameter ranges of lipoprotein subclasses when measured by Nuclear Magnetic 
Resonance Spectroscopy (NMR). 
NMR Lipoprotein Parameter Diameter Range (nm) 
VLDL 
Large VLDL/chylomicrons >60 
Medium VLDL 35–60 
Small VLDL 27–35 
LDL 
Large LDL 21.2–23 
Small LDL 18–21.2 
HDL 
Large HDL 8.8–13 
Medium HDL 8.2–8.8 
Small HDL 7.3–8.2 
Anthropometric and smoking measures Clinical characteristics were taken at the study clinics at the 
baseline visit (Figure 1). Questionnaires were administered to collect demographic data and 
information on lifestyle attributes and medical history. Smoking status was collected by a question 
with a dichotomous outcome, which asked whether the participant was a current smoker. During this 
visit BMI was collected by trained research staff. 
2.3. Genotyping 
Genotyping Although SNPs were selected from previous literature, the data were taken from GOLDN’s 
available GWAS data. SNPs were genotyped using the Affymetrix Genome-Wide Human 6.0  
array (Affymetrix, Santa Clara, CA, USA) and the Birdseed calling algorithm [35]. The samples were 
processed in two different batches by two different technicians. Call rates by plate and by technician were 
similar, thus, we determined that there were no significant batch effects. We used MACH software [36]  
to impute untyped SNPs using Human Genome Build 36, CEU population, as the reference, which created 
a hybrid dataset that included 2,543,887 SNPs, of which 584,029 were initially genotyped in the  
GOLDN population. 
Quality Control As SNPs were selected from the available GWAS data, they were subject to the same 
quality control measures as our GWAS studies. For the whole GWAS data, SNPs were excluded that were 
monomorphic (55,530) or had a call rate <96% (82,462). Additionally, SNPs were excluded based on the 
number of families with Mendelian errors as follows: For minor allele frequency (MAF) ≥20%, removed 
if errors were present in >3 families (1486 SNPs); for 20% > MAF ≥10%, removed if errors were present 
in >2 families (1338 SNPs); for 10% > MAF ≥5%, removed if errors were present in >1 family  
(1767 SNPs); for MAF <5%, removed if any errors were present (9592 SNPs). 
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SNP selection SNPs were selected from a GWAS by Chasman and colleagues [9]. SNP-phenotype 
associations with NMR data in other recent studies were not included because they were not on direct 
NMR phenotypes, but rather latent factors created from the phenotypes [10], or because the subclass 
division was based on different diameter ranges than those available in GOLDN, and so it was not 
clear how to harmonize the phenotype in replication [11]. The initial discovery GWAS by Chasman 
and colleagues was conducted in 17,296 women of self-reported European ancestry forming the study 
population for the Women’s Genome Health Study (WGHS). Replication of signals was performed in 
two independent populations: The Framingham Heart Study (FHS) and the Precocious Coronary 
Artery Disease (PROCARDIS) study. One hundred and eighty-nine SNP-phenotype associations 
(which were replicated in both independent samples) pertained to phenotypes available in the GOLDN 
dataset (those not relating to lipoprotein subclasses e.g., ApoA1 levels were not available and so 
excluded from the current analysis). An additional 10 SNPs (forming 26 SNP-phenotype associations 
as most SNPs were associated with more than one phenotype) were not available in the GOLDN 
dataset, and 2 SNPs (3 SNP-phenotype associations) did not pass GOLDN quality control (as above) 
leaving a final selection of 160 SNP-phenotype associations included in this analysis. 
2.4. Statistical Methods 
Phenotypes. Fenofibrate response was defined as the ratio of pre- to post-fenofibrate values, 
evaluated while fasted. For both fasting, and fenofibrate response, skewed phenotypes (all except at 
fasting: concentration of small LDL, number of HDL particles, concentration of large HDL, 
concentration of small HDL, LDL diameter, and HDL diameter. For fenofibrate response: number of 
LDL particles, LDL diameter, and HDL diameter) were log transformed to approximate normality 
before analysis. To test whether there were significant differences NMR measures before and after the 
fenofibrate trial, paired t tests were conducted. Please check the highlights. 
SNP-phenotype associations. We used a linear mixed model. The effects of SNP genotypes 
(categorical variable with three classes for genotyped SNPs; continuous variable on a scale of 0–2 for 
imputed SNPs) were treated as fixed effects in an additive model, and the dependencies among members 
within each family were treated as random effects. Age, smoking status, BMI and gender were included 
in the model as covariates, as in the previous GWAS [9]. Field center was treated as an additional 
covariate. The minor allele was the coded allele. Pre-treatment fasted SNP-phenotype associations are 
available in Supplementary Table S1. 
In replicating work from a previous study, we chose the same covariates in the genetic association 
analyses. These did not include baseline triglycerides (TGs). The justification behind this approach is 
the evidence that the pharmacological action of fenofibrate is the same in normolipidemics as 
hyperlipidemics, although hyperlipidemics may show slightly stronger responses [37–39], and the lack 
of evidence to suggest that the genetic mediators of fenofibrate pathways would differ across normo- and 
hyper-lipidemics. However, we also present the genetic analyses stratified by TG levels (baseline 
fasting TG ≥150 mg/dL) noting that the results do not change according to pre-treatment TG levels 
(Supplementary Table S2). 
GRS-phenotype associations. Unweighted GRSs were constructed as unweighted sums as the 
original GWAS meta-analysis was conducted on a population which may be described as “modest” for 
current GWAS and unweighted GRS maybe more robust against errors in estimating the effect sizes 
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arising from limited sample size [39]. In addition, unweighted GRS are more suitable at reducing 
increased estimates of association due to population heterogeneity, population substructure, and 
“winner’s curse” bias [39]. For the individual SNP-phenotype associations the genotypes were 
rescored where necessary, based on the original direction of effect in the published meta-analytic 
GWAS [9] (Supplementary Table S2). As SNPs could be associated with more than one lipoprotein 
measure in the previous GWAS, they therefore could contribute to more than one GRS in the current 
analyses. For the GRS, where the original beta was negative for a given SNP-phenotype association, 
the genotype was rescored such that the major allele was the coded allele. Where the original beta was 
positive, the minor allele remained the coded allele. This resulted in genotypes being scored both ways 
(with the minor allele and the major allele as the coded allele) based on the particular phenotype.  
The direction of the original betas for each SNP-phenotype association are available in Supplementary 
Table S2. The GRS for each phenotype was then created by summing the alleles (genotyped SNPs) 
and allele dosages (imputed SNPs) for all SNPs within the previously reported SNP-phenotype 
associations for a given measure [9].  
GRS was used as a continuous predictor in mixed linear models as outlined for the SNP-phenotype 
associations, above. The results for the GRS-phenotype associations were corrected using a Bonferroni 
correction, based on the number of calculated GRSs (n = 14). This gave rise to a p = 0.004 (α = 0.05/14). 
F-values from the mixed linear models were converted to effect sizes (cohen’s d; δ). 
3. Results 
Changes in lipoprotein subclasses. Participant characteristics for the GOLDN study, including the 
change in lipoprotein measures pre- and post-fenofibrate, are shown in Table 2. As expected, we saw a 
significant increase in the average size of LDL particle (p < 0.0001) which resulted from a decrease in 
the concentration of small LDL (p > 0.0001); the concentration of large LDL did not change (p = 0.19; 
Table 2). All VLDL subclass concentrations decreased (p < 0.0001) in such a manner that the overall 
diameter of VLDL particles remained the same (p = 0.14; Table 2). The small and large HDL subclass 
concentrations also decreased (p = 0.003 and p < 0.0001 respectively) and the medium HDL subclass 
concentration increased (p < 0.0001) yielding an overall decrease in HDL diameter (p < 0.0001; Table 2). 
GRS-phenotype associations with NMR measures at baseline, and NMR responses to fenofibrate. 
Almost all GRSs were associated with baseline NMR data (p < 0.05), although not all associations 
survived a correction for multiple testing. The exception was the association between VLDL total 
particles and GRS (p = 0.11). Nine out of 14 significant GRS-phenotype associations (concentration of 
small VLDL particles, concentration of medium VLDL particles, average VLDL diameter, concentration 
of large LDL particles, LDL total particle number, concentration of small HDL particles, concentration of 
medium HDL particles, concentration of large HDL particles, HDL total number of particles and HDL 
diameter) survived a Bonferroni correction which gave rise to an corrected p = 0.004 (Table 3). None of 
the GRS were associated with fenofibrate response after a Bonferroni correction (Table 3). As 
fenofibrate is indicated for use in hypertriglyceridemia GRS-phenotype associations were conducted 
stratified by TG levels (baseline fasting TG ≥ 150 mg/dL). Results remained the same in that neither 
normotriglyceridemic, nor hypertriglyceridemic samples showed significant GRS-phenotype associations 
with responses to fenofibrate (Supplementary Table S2).  
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Table 2. Means (standard deviation) or percentage for demographic, anthropometric and 
fasting lipoprotein characteristics of the GOLDN study population.  
Age, year 48.42 (16.34) 
Gender, % male 48.28 
Smoker, % current 7.79 
BMI 28.25 (5.62) 
 Baseline Post-Fenofibrate p 
Small VLDL concentration, nmol/L 32.93 (21.89) 22.83 (15.83) <0.0001  
Medium VLDL concentration, nmol/L 37.49 (36.74) 18.46 (20.44) <0.0001  
Large VLDL concentration, nmol/L 3.93 (7.68) 2.09 (3.24) <0.0001  
VLDL total particles; nmol/L 74.38 (50.81) 43.41 (31.73) <0.0001  
VLDL diameter; nm 51.39 (7.86) 51.84 (8.71) 0.14 
Small LDL concentration, nmol/L 925.64 (557.03) 779.49 (373.04) <0.0001  
Large LDL concentration, nmol/L 407.11 (272.91) 397.23 (201.37) 0.19 
LDL total particles; nmol/L 1375.33 (437.46) 1209.35 (380.68) <0.0001  
LDL diameter; nm 20.81 (0.88) 20.90 (0.58) <0.0001  
Small HDL concentration, nmol/L 21.65 (5.54) 20.76 (6.71) 0.003  
Medium HDL concentration, nmol/L 3.00 (3.61) 5.92 (4.80) <0.0001  
Large HDL concentration, nmol/L 6.32 (3.54) 5.73 (3.25) <0.0001  
HDL total particles; nmol/L 30.97 (5.63) 32.42 (5.95) <0.0001  
HDL diameter; nm 8.85 (0.45) 8.73 (0.39) <0.0001  
Baseline fasting TG < 150 mg/dL (N = 544) 
Small VLDL concentration, nmol/L  28.13 (15.67) 18.60 (12.60) <0.001 
Medium VLDL concentration, nmol/L 21.06 (14.68) 12.34 (11.07) <0.001 
Large VLDL concentration, nmol/L 1.39 (1.53) 0.95 (1.22) <0.001 
VLDL total particles; nmol/L 50.62 (24.01) 31.92 (19.76) <0.001 
VLDL diameter; nm 50.73 (8.20) 51.12 (9.19) 0.44 
Small LDL concentration, nmol/L 705.82 (403.85) 662.38 (261.74) <0.001 
Large LDL concentration, nmol/L 478.91 (252.68) 398.55 (184.97) <0.001 
LDL total particles; nmol/L 1213.23 (364.60) 1073.37 (279.02) <0.001 
LDL diameter; nm 21.14 (0.73) 21.01 (0.53) 0.001 
Small HDL concentration, nmol/L 20.53 (5.17) 19.25 (6.08) <0.001 
Medium HDL concentration, nmol/L 3.34 (3.54) 6.67 (4.47) <0.001 
Large HDL concentration, nmol/L 7.27 (2.30) 6.42 (3.30) <0.001 
HDL total particles; nmol/L 31.15 (5.18) 32.35 (5.44) <0.001 
HDL diameter; nm 8.97 (0.43) 8.83 (0.34) <0.001 
Baseline fasting TG ≥ 150 mg/dL (N = 248) 
Small VLDL concentration, nmol/L  43.62 (28.93) 31.97 (18.10) <0.001 
Medium VLDL concentration, nmol/L 74.12 (44.03) 31.67 (28.32) <0.001 
Large VLDL concentration, nmol/L 9.60 (11.74) 4.55 (4.60) <0.001 
VLDL total particles; nmol/L 127.38 (54.65) 68.22 (37.96) <0.001 
VLDL diameter; nm 52.84 (6.85) 53.39 (7.35) 0.09 
Small LDL concentration, nmol/L 1415.81 (539.35) 1032.66 (445.66) <0.001 
Large LDL concentration, nmol/L 247.00 (247.40) 413.84 (232.50) <0.001 
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Table 2. Cont. 
Baseline fasting TG ≥ 150 mg/dL (N = 248) 
LDL total particles; nmol/L 1736.81 (488.611) 1503.32 (404.81) <0.001 
LDL diameter; nm 20.07 (0.72) 20.67 (0.62) <0.001 
Small HDL concentration, nmol/L 24.14 (5.54) 24.03 (8.84) 0.36 
Medium HDL concentration, nmol/L 2.23 (3.65) 4.30 (5.08) <0.001 
Small VLDL concentration, nmol/L  43.62 (28.93) 31.97 (18.10) <0.001 
Medium VLDL concentration, nmol/L 74.12 (44.03) 31.67 (28.32) <0.001 
Large VLDL concentration, nmol/L 9.60 (11.74) 4.55 (4.60) <0.001 
Table 3. Associations between genetic risk scores and baseline NMR measures, and between 
genetic risk scores and the response of NMR measures to a 3-week fenofibrate trial. 
NMR Measure Min Max Mean (SD) 
Genetic Risk Score 
GRS-Phenotype Associations 
Baseline Fenofibrate Response 
F-Value δ p F-Value δ p 
Full GOLDN sample (n = 817) 
Small VLDL 
concentration 9.44 22.02 
15.75 
(2.11) 0.04 0.01 0.85 0.45 0.05 0.50 
Medium VLDL 
concentration 5.26 13.65 
9.79 
(1.49) 3.97 0.14 0.04 0.39 0.04 0.53 
Large VLDL 
concentration 9.16 22.49 
15.87 
(2.34) 0.66 0.06 0.41 1.77 0.09 0.18 
VLDL total 
particles 1.01 8.34 
5.15 
(1.16) 26.37 0.36 <0.0001 * 0.50 0.05 0.48 
VLDL diameter 1.00 10.09 5.32 (1.61) 2.03 0.10 <0.15 0.01 0.007 0.93 
Small LDL 
concentration 18.00 27.99 
23.25 
(1.63) 8.90 0.21 0.003 * 1.65 0.09 0.20 
Large LDL 
concentration 8.37 24.01 
16.29 
(2.48) 11.48 0.24 0.0007 * 0.00 0 0.99 
LDL total particles 5.96 19.65 12.39 (2.16) 8.10 0.20 0.004 * 0.24 0.03 0.62 
LDL diameter 0.14 7.97 3.55 (1.25) 7.04 0.19 0.008 * 0.24 0.03 0.63 
Small HDL 
concentration 5.00 18.01 
10.64 
(2.06) 13.86 0.26 0.0002 * 0.02 0.01 0.87 
Medium HDL 
concentration 7.27 17.27 
12.25 
(1.77) 9.11 0.21 0.0003 * 6.38 0.17 0.01 
Large HDL 
concentration 5.98 19.05 
12.26 
(1.97) 12.14 0.24 <0.0005 * 0.19 0.03 0.67 
HDL total particles 1.19 10.88 5.91 (1.66) 2.56 0.11 0.11 0.35 0.04 0.56 
HDL diameter 6.80 20.46 13.50 (2.23) 10.05 0.22 <0.002 * 0.54 0.05 0.46 
* Significant at a Bonferroni corrected α = 0.004. 
  




This study examined whether the change in lipoprotein subclass concentration and distribution after a 
three week fenofibrate trial was associated with SNPs previously identified with fasting NMR-measured 
lipoprotein phenotypes. We report changes in all lipoprotein measures, with the exception of VLDL 
distribution and the concentration of large LDL particles, after fenofibrate treatment. GRSs, composed 
of previously validated SNPs, were strongly associated with most baseline NMR phenotypes, but were 
not predictive of the response of those phenotypes to fenofibrate. 
As expected from previous literature, LDL particle size significantly increased after the fenofibrate 
treatment [13,14,18]. In our study, this arose from a decrease in the concentration of small LDL 
particles, while the concentration of large LDL particles remained the same. This study provides 
additional support for the notion of protective effects of fenofibrate treatment for cardiovascular 
disease risk, as it is the smaller, more dense LDL particles that are considered to occur with insulin 
resistance and convey increased atherosclerosis risk, although this conclusion must be considered 
alongside an understanding of any lipid response to fenofibrate which is not examined in the current 
analyses [2,4,7,40–42]. 
The effects of fenofibrate on other fractions of lipoprotein are less well studied. We report that the 
concentration of all VLDL subfractions significantly decreased, such that the overall distribution 
remained the same, supporting a single previous report [25]. An increase in VLDL particles, especially 
the large subfraction, occurs in insulin resistance [40,43] and confers increased cardiovascular disease 
risk [44,45]. However any reduction in cardiovascular disease risk associated with the decrease in 
VLDL and small LDL particles, may have to be considered against an increase in small HDL particles. 
Although HDL may be beneficial in preventing atherosclerosis through its role in reverse cholesterol 
transport, this processes is associated with the large HDL subspecies [25]. We report a significant 
increase in small HDL particles, suggestive of an increase in cardiovascular disease risk. However, this 
may be partially offset by a simultaneous increase in medium and large HDL particle concentrations as 
evidenced by the significant shift to an overall larger HDL diameter, even though the small subfraction 
shows the greatest increase. 
We created GRSs from previously validated SNP-phenotype associations with NMR data [9]. With the 
exception of total number of VLDL particles, all GRSs showed at least a trend toward association with 
NMR phenotypes in that they were significant, but did not survive a stringent Bonferroni correction for 
multiple testing. Several phenotypes remain significant even after correction: GRS-phenotype associations 
held for medium VLDL concentration, VLDL diameter, large LDL concentration, LDL total particles, 
small medium and large HDL concentrations, HDL total particles and HDL diameter. However, we 
saw no significant GRS-phenotype associations with responses to fenofibrate. Whether genetic loci 
associated with any baseline measures also associate with the response of those measures to 
interventions is a largely unstudied question. Previous data from our lab indicate that for lipid 
measures, only 7% of baseline genetic associations also associate with fenofibrate response [46].  
The current study showed no shared genetic associations with baseline and response phenotypes, 
which seemed to confirm the broader pattern of results from the previous study. However, we cannot 
exclude the possibility that our loci were less robustly validated than those employed in the lipid study, 
due to fewer research on lipoprotein subfractions vs. traditional lipids. These are the first investigations 
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of which we are aware that address this broader question. Certainly, this study represents the first 
investigation focusing on NMR data. We conclude that on current evidence, different genetic loci 
associate with baseline and fenofibrate response lipoprotein phenotypes. 
The results of this study must be considered in the light of several limitations. First, as the first such 
study, replication is a key issue, although we are confident that the SNPs associated with fasting NMR 
lipoproteins in free-living populations have been robustly validated. Second, not all SNPs from the 
original GWAS were available in our data, either due to our quality control measures or genotyping 
platform. Proxy SNPs were not available in a large number of cases, and these SNPs are excluded 
from analysis. However, as they are likely to only contribute a small amount of information to the 
overall GRS we do not believe this that would affect the overall conclusion of our study.  
Nonetheless, to establish the validity of the GRS in and of itself, replication is vital. Finally, as a 
clinical trial, we did not have the power to fully replicate all of the previous SNP-phenotype 
associations in baseline NMR data although our GRSs, in general, showed strong GRS-phenotype 
associations. For replication, we would also encourage larger samples for such, where feasible, and 
additionally a less conservative correction for multiple testing—here we chose the most conservative 
Bonferroni correction as our analyses remain the first to construct such a GRS from the previous data. 
This would allow a more finally nuanced analysis of individual SNP-phenotype associations for the 
fenofibrate responses. 
Our results may still have important implications for future practice. We have shown fenofibrate to 
be an important modulator of many lipoprotein subclass measures. However, what modulates 
individual differences in the changes of these phenotypes at the genetic level, remains an unanswered 
question. Addressing this may one day help with understanding the pathways through which 
fenofibrate works in individuals, to target more effective treatment. 
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